CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
CVN424drug
Likely dose
CVN424 150 mg (tablet or suspension formulation)AI-extracted
Key inclusion· 4
  • ✓Healthy male or female adults aged 18 to 55 years
  • ✓Weight ≥45 kg with BMI 18.0–35.0 kg/m²
  • ✓Medically healthy with no clinically significant abnormalities in medical history, physical exam, vitals, ECG, and labs (hematology, chemistry, urinalysis)
  • ✓Able to understand and comply with protocol and informed consent
Key exclusion· 15
  • ✕Vegetarian, vegan, lactose intolerant, or follows a Kosher diet
  • ✕Clinically significant neurologic or other disorder reasonably expected to impact study participation or confound results
  • ✕Current or recent (within 6 months) gastrointestinal disease affecting drug absorption (malabsorption, prior bariatric surgery, bowel resection)
  • ✕History of cancer or malignancy, except low-grade cervical intraepithelial neoplasia, low-grade prostate cancer, or 5-year cancer-free survivors of basal/squamous cell carcinoma

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05635461
NCT05635461Phase 1Completed
CompareCT.gov

A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension &Tablet Formulations Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers

Cerevance Beta, Inc.·interventional·Posted Dec 2, 2022·Updated Sep 19, 2024

In Brief

A Phase 1 clinical trial evaluating CVN424 for Parkinson's Disease. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedDec 2, 2022
Enrollment StartOct 9, 2022
Primary CompletionNov 11, 2022
Study CompletionNov 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.6 years ago

Interventions

CVN424drug

150 mg of either tablet or suspension formulation